Details

Autor(en) / Beteiligte

• Mares, Alina
• Miah, Afjal H
• Smith, Ian E D
• Rackham, Mark
• Thawani, Aditya R
• Cryan, Jenni
• Haile, Pamela A
• Votta, Bartholomew J
• Beal, Allison M
• Capriotti, Carol
• Reilly, Michael A
• Fisher, Don T
• Zinn, Nico
• Bantscheff, Marcus
• MacDonald, Thomas T
• Vossenkamper, Anna
• Dace, Phoebe
• Churcher, Ian
• Benowitz, Andrew B
• Watt, Gillian
• Denyer, Jane
• Scott-Stevens, Paul
• Harling, John D

Titel

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Ist Teil von

• Communications biology, 2020-03, Vol.3 (1), p.140, Article 140

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional small-molecules that can promote the rapid and selective proteasome-mediated degradation of intracellular proteins through the recruitment of E3 ligase complexes to non-native protein substrates. The catalytic mechanism of action of PROTACs represents an exciting new modality in drug discovery that offers several potential advantages over traditional small-molecule inhibitors, including the potential to deliver pharmacodynamic (PD) efficacy which extends beyond the detectable pharmacokinetic (PK) presence of the PROTAC, driven by the synthesis rate of the protein. Herein we report the identification and development of PROTACs that selectively degrade Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) and demonstrate in vivo degradation of endogenous RIPK2 in rats at low doses and extended PD that persists in the absence of detectable compound. This disconnect between PK and PD, when coupled with low nanomolar potency, offers the potential for low human doses and infrequent dosing regimens with PROTAC medicines.